Agent eliciting immunostimulating effect
FIELD: medicine, immunology.
SUBSTANCE: invention is designated for treatment and prophylaxis of diseases associated with the immune system insufficiency in chronic relapsing inflammatory diseases, in cases of insufficient effectiveness of antibacterial and anti-inflammatory therapy. Agent eliciting the immunostimulating effect comprises dropwort (Filipendula ulmaria L.) dried, milled, above-ground part, dropwort (Filipendula ulmaria L. Maxim.) dry an aqueous or dry alcoholic extract prepared in the definite ratio of raw : extractant.
EFFECT: valuable medicinal properties of agent.
4 cl, 4 tbl, 4 ex
The invention relates to medicine, more specifically to immunology and AIDS, having an immunostimulating action, used for the treatment and prevention of diseases associated with deficiency of the immune system in chronic relapsing diseases of an inflammatory nature, in cases of lack of effectiveness of antibacterial and anti-inflammatory therapy.
Known means of synthetic and natural origin used to stimulate the immune system. These include substances of microbial (bacterial and fungal) origin (prodigiozan, pyrogenes, ribomunyl, nukleinat sodium); substances of vegetable origin (tonsillar, immunal, different preparations of Echinacea). Immunoregulatory peptides of natural origin: drugs from the thymus gland (thymalin, taktivin, timoptic, vilonen); preparations of spleen (splenin); preparations of bone marrow: mielopid. Cytokines (natural and recombinant). Synthetic and chemically pure immunomodulators: analogs of drugs of endogenous origin (timogen, immunofan, Likopid); drugs (dalargin, levamisole, Dibazol, ditiocarb, polyoxidonium) [2, 3, 5, 7, 8, 9].
The presence of side effects in the majority of the listed drugs in the form of chills, fever headache, dyspeptic disorders, pain at the site of parenteral administration of the drug, adverse effects during pregnancy, asthma, allergic diseases greatly restrict the use of many drugs with immune stimulating effects.
Closest to the claimed tool is of plant origin, having an immunostimulating action, tincture of Echinacea purpurea (Echinacea purpurea (L) Moench (Asteraceae)) (prototype) .
Development of new natural immunomodulators with low side effects that are relevant.
The problem solved by this invention is an expanding Arsenal of low means, having an immunostimulating action, for prophylaxis and treatment of acute and chronic inflammatory processes, immune disorders of different origin and other conditions associated with low activity of the immune system without side effects and with more prolonged stimulant.
This object is achieved in that as a means of having an immunostimulating action, use dried powdered aerial part of meadowsweet Filipendula ulmaria (L) Maxim (LV 1); a dry aqueous extract of dried powdered aerial parts meadowsweet is atlantaga Filipendula ulmaria (L) Maxim when the ratio of raw material : solvent 1:9 (LV 2); a dry alcoholic extract 40 percent ethyl alcohol dried powdered aerial parts of meadowsweet Filipendula ulmaria (L) Maxim when the ratio of raw material : solvent 1:9 (LV 3); dry alcoholic extract 70 percent ethyl alcohol dried powdered aerial parts of meadowsweet Filipendula ulmaria (L) Maxim when the ratio of raw material : solvent 1:9 (LV 4).
Meadowsweet (Filipendula vyazolistny) - Filipendula ulmaria (L) Maxim. The family Rosaceae. A perennial herb with a creeping rhizome and high solid ribbed stems, up to 150, see the Leaves are thick, broken-pinnate, green top, white bottom. Flowers yellowish-white, gathered in a dense panicle. Blooms in June-July.
Common in forest and forest-steppe and mountain-forest belt everywhere. Grows in damp woods and groves, stands on the banks of rivers and marshes, wet meadows [4, 6].
The plant contains an essential oil consisting of salicylic aldehyde and heliotropine, ascorbic acid, carotene, the glycoside serein, vanilla, terpenes, free salicylic acid, anthocyanin, flavone, tanning matters and pyrogallol groups, volatile[1, 4, 6].
New in the present invention is that identified a new property aerial parts of meadowsweet (Filipendula ulmaria (L) Maim), namely its immunostimulating effect. He has a longer-lasting stimulatory effect on the performance of specific humoral immune response and nonspecific resistance of the organism in comparison with widely used in practical medicine Echinacea purple.
From literature data it is known the use of drugs of meadowsweet (Filipendula ulmaria (L.) Maxim) in the form of a decoction made from the roots and flowers as an antiseptic, anti-inflammatory, diuretic, astringent remedies for eczema, atopic dermatitis, gout, rheumatism, edema, pleurisy [1, 3], in the form of lotions and mouthwashes with stomatitis, gingivitis, gum disease . The decoction is used for gynecological disorders, in the treatment of purulent wounds, ulcers, [1, 4]. In clinical medicine is used as an integral part of medicine, Zdenko assigned when the bladder papillomatosis and anatsidnyh gastritis, tachycardia [I]. Shows high antioxidant activity of the decoction of the flowers of meadowsweet (Fihpendula ulmdria (L.) Maxim) [Melpomenia, 2000]. Immunostimulatory properties of meadowsweet not described.
Main registered drugs meadowsweet are: meadowsweet flowers (haemostatic, protivogemorroidalny, diuretic), registration number 88/229/7; meadowsweet castelpetroso to revise and root (an integral part of medicine, Zdrenka, hemostatic, protivogemorroidalny, diuretic), registration number 74/270/6.
The authors are not found in the analyzed literature, this combination of essential features for use as an immunostimulating agent of above-ground dried crushed part of meadowsweet, dry, aqueous and alcoholic extract.
A comparison of the claimed funds: LV 1, LV 2, LV 3, LV 4 with known shows that first proposed the use of extracts from dried powdered aerial parts of meadowsweet as an immunostimulating agent.
Thus, the claimed means of having immunostimulant effect, meets the criteria of the invention of "Novelty" and "Inventive step"because it is not obvious to a person skilled in the art. The proposed solution meets the criteria of the invention "Industrially applicable"because it can be successfully used in practical health care.
Immunotropic activity funds: LV 1, LV 2, LV 3, LV 4, was studied in experiments on animals, and shows its immunostimulating effect in comparison with the immunostimulating action of tinctures of Echinacea purpurea. We studied the activity of extracts from the aerial parts of meadowsweet, polucen is x in the following ways:
Example 1. the aboveground part of meadowsweet was dried and crushed to fine powder (LV 1);
Example 2. dried powdered aerial part of meadowsweet was boiled in distilled water at the ratio of raw material and extractant 1:9 on a water bath for 15 min, then was cooled for 45 min, filtered through 4 layers of gauze, and then was evaporated to dryness (LV 2);
Example 3. dried powdered aerial part of meadowsweet was filled with 40 percent ethyl alcohol in the ratio of raw material and extractant 1:9, insisted 14 days, the extract obtained was filtered through 4 layers of gauze, and then was evaporated to dryness (LV 3);
Example 4. dried powdered aerial part of meadowsweet filled in 70 percent ethyl alcohol in the ratio of raw materials and extravanga 1:9, insisted 14 days, the extract obtained was filtered through 4 layers of gauze, and then was evaporated to dryness (LV 4).
Material and methods.
The experiments were performed on 180 mice of both sexes CBA/CaLac 1 category (conventional linear mouse) (certificate available)obtained from the nursery of the Institute of pharmacology of RAMS Siberian branch. The animals were conducted in accordance with rules adopted by the European Convention for the protection of vertebrate animals used for experimental and other scientific purposes Strasbourg, 1986). Before and during the experiment, the mouse was in standard plastic cages (10-12 individuals) with small wood chips on a standard diet. All experiments were conducted in the autumn-winter period.
Experimental model of cytotoxic immunosuppression was created using standard drug cyclophosphamide (production of Saransk plant "Biochemist"), which was dissolved in sterile saline and were injected into mice intraperitoneally once at the maximum tolerated dose (250 mg/kg). Model experimental stress reproduced by 16-hour immobilization in a hollow closed cylinder.
In this work, we used a tincture of Echinacea purpurea 40% ethyl alcohol (NEP) "Echinacea-Galeno Pharm" (JSC "Pharmaceutical factory of St. Petersburg") (prototype), as the comparison drug. Before the introduction of the experimental animals, the extract was diluted with distilled water 2 times and evaporated to the original volume to remove the alcohol. Tincture of Echinacea purpurea and the proposed means of LV 1, LV 2, LV 3, LV 4, obtained in accordance with examples 1, 2, 3 and 4, animals were injected through a tube into the stomach within 5 days from the experimental exposure dose of 50 mg/kg as a suspension in distilled water to a volume of 0.2 ml of the Control animals were injected with the appropriate volume of the distilled water.
In the study of humoral immune response of mice were immunized minimum dose of sheep erythrocytes (DL) - 5× 106/mouse (once intraperitoneally in a volume of 0.2 ml) at the end of the 5-day course introducing the NEP or LV 1, 2, 3 and 4. On day 7 after immunization were determined absolute (× 106/organ) number of antibody productive cells (AFC) in the spleen of mice according to the method of Cuningham  and the tiger (Log2) antibodies (AT) in the serum using standard reaction of haemagglutination (DSA).
The phagocytic activity of peritoneal macrophages was determined by . After decapitate mice were injected intraperitoneally with 5 ml of physiological solution and produced the fence contents. The concentration of living cells brought to 0.75× 106cells/ml of the resulting suspension was poured into plastic Petri dishes with a diameter of 40 mm, incubated 1 hour at 37° C, then poured adosados and was added a solution of neutral red, made of 1 part saturated solution of neutral red and 99 parts of Hanks solution. After incubation for 1 hour at 37° adosados poured in each Cup was added to 3 ml lyse solution (8 ml of 0.2 M solution of PA2NRA4·N2About connected with 12 ml of 0.1 M citric acid solution, using 1 N NaOH solution was made pH to 4.2; 24 parts received nitrate buffer is added 76 parts 96% ethanol) and stirred. The solution was poured into the cell width of 0.5 cm and measured the optical density on the photocolorimeter CPK-2MP at a wavelength of 540 nm, expressing the activity of peritoneal macrophages in units of optical density x1000.
Statistical processing of the results was carried out using the statistical software package "Statistica" with a preliminary estimate of the normal distribution and the t-student test.
The results of the study.
In the study of the absolute amount of antibody productive cells in the spleen of mice treated with LV 1, LV 2, LV 3, LV 4 in norm and after the extreme effects (immobilization stress, cyclophosphamide), it was revealed that LV 1, LV 2, LV 3, LV 4 on day 7 observations led to the normalization of the absolute number of KLA in animals immunized with EB on the background exposure to stress or administration of cyclophosphane, in contrast to the experimental group who did not receive the proposed means (Table 1).
Administration of the extract NEP (prototype) led to the increase of the studied index on day 7 observations, but the absolute amount of the KLA in these experimental groups was statistically lower than in the introduction of the proposed tools (Table 1).
The content of serum hemagglutinins class M with the introduction of the proposed tools on the 7 day of observations was reduced in the group animal is, immunized DL after immobilizing stress, in comparison with the corresponding group not treated with the drug (Table 2). This fact indicates the offset switching synthesis of IgM to IgG in the earlier period, which is indirectly confirmed by the increase on day 7 research hemagglutinin titer of class G to the corresponding values in the control group (Table 3). After the introduction of the proposed means to mice given cyclophosphamide, there was an increase tiger IgM antibodies in comparison with the corresponding control group (Table 2). The titer of serum hemagglutinin class M with the introduction of the NEP group of animals after application of cyclophosphamide was on day 7 of the studies was significantly lower than in the groups of animals treated with the proposed tool: LV 1, LV 2, LV 3, LV 4.
Dynamics of the content of immunoglobulines class G in the serum of animals treated with the NEP, was similar to the dynamics of this indicator in the groups of animals after the course the introduction of the proposed tools.
When comparing the phagocytic activity of peritoneal macrophages in the introduction as the NEP (prototype), LV 1, LV 2, LV 3 and LV 4 (claimed vehicle) on day 7 observations revealed a stimulating effect of all the drugs in the target rate in the group who underwent immobilization stress, or the introduction of qi is lafontana compared to the respective control groups without the injection.
Thus, the proposed means of LV 1, LV 2, LV 3, LV 4 resulted in a more pronounced and prolonged stimulation of the humoral immune response than the introduction of the NEP (prototype). This LV 1, LV 2, LV 3 and LV 4 almost similar level of impact on the specific humoral response. The influence of nonspecific resistance of the organism (the phagocytic activity of peritoneal macrophages) LV 1, LV 2, LV 3 and LV 4 (rated medium) was comparable with the effect of the NEP (prototype).
1. Savrasov VI, Kitaev R.I., Khmelev CYP Medicinal plants: Therapeutic and prophylactic use. Voronezh: Publishing house of Voronezh state University, 1993. - 480 S.
2. Leskov VP, Chiradeep A.N., Gorlina NICHOLAS, Novozhenov VG Clinical immunology for clinicians. M., 1997. - 124 S.
3. Mashkovsky PPM Medicines. In 2 parts.- 12th ed., revised and expanded. M.: Medicine, 1993.
4. Minaev VG Medicinal plants of Siberia. Novosibirsk: Nauka, 1991. - 431 S.
5. D.K. Novikov, Derkach YU.N., Novikov P.D. Immunotropic drugs // In the world of drugs. - 1999. No. 2. - P.48-57.
6. Plant resources of the USSR: Flowering plants, their chemical composition and use; Family Hydrangeaceae - Haloragaceae, Leningrad: Nauka, 1987. - 326 S.
7. Xed B.C., Sergeev, A.S., Korostelev, S.A. the Analysis of contemporary trends in the creation of immunotropic of the Experimental and clinically. Pharmacol. - 1995. No. 3. - P.3-7.
8. Khaitov R.M P.M., Pinegin B.V. Basic concepts of immunotropic drugs // Immunology. - 1996. No. 6. - P.4-9.
9. Shirinsky B.C. Secondary immunodeficiencies problems of diagnosis and treatment. Novosibirsk, 1997. - 111
10. Cuningham, A.I. // Nature. - 1965. - V.207. - R.
11. Vrav B., J. Hoebeke, Saint-Girillain M. e.a. // Scand. J. Immunol. - 1980. - Vol.11 - P.147-153.
|Intact control||2,28± 0,18|
|Immunization DL||of 11.69± 0,29* * *|
|Immobilization + immunization||a 3.87± 0,24* # # #|
|Cyclophosphamide + immunization||4,54± 0,53* # # #|
|NEP + immunization||11,98± 0,13* * *|
|NEP + immobilization + immunization||6,54± 0,52* * * # # $|
|NEP + cyclophosphamide + immunization||9,24± 0,98* * * # $$|
|LV + immunization||was 9.33± 0,67* * *|
|LV + immobilization + immunizatio||of 10.58± 0,78* *|
|LV + cyclophosphamide + immunization||a 9.09± 0,75* * *|
|LV + immunization|
|LV + immobilization + immunization||was 9.33± 0,67* * *|
|LV + cyclophosphamide + immunization||8,63± 1,01* * * # #|
|LV + immunization||9,14± 0,17* * *|
|LV + immobilization + immunization||10,24± 0,58* *|
|LV + cyclophosphamide + immunization||was 12.75± 0,81* * * $$$|
|LV + immunization||13,12± 0,97* * *|
|LV + immobilization + immunization||10,89± 0,84* *|
|LV + cyclophosphamide + immunization||9,98± 0,81* * * $|
|Note (hereinafter in tables 2, 3). * - reliability of differences with the background group; # - with the control group EB $ - with an appropriate control group (group immunized EB on the background of injection).|
|Immunization DL||2,75± 0,92|
|Immobilization + immunization||3,99± 0,52# # #|
|Cyclophosphamide + immunization||2,32± 0,32#|
|NEP + immunization||3,05± 0,22|
|NEP + immobilization + immunization||3,63± 0,92# $|
|NEP + cyclophosphamide + immunization||2,92± 0,57$|
|LV +immunization||2,95± 0,97|
|LV +immobilization + immunization||3,00± 0,78# $|
|LV +cyclophosphamide + immunization||2,25±0,75#|
|LV + immunization||2,65± 0,65|
|LV + immobilization + immunization||2,95± 0,47# $$|
|LV + cyclophosphamide + immunace||2,50± 0,41|
|LV + immunization||2,25± 0,22|
|LV + immobilization + immunization||3,20± 0,16# $|
|LV + cyclophosphamide + immunization||3,40± 0,38# # $$|
|LV + immunization||2,00± 0,35# #|
|LV + immobilization + immunization||3,00± 0,74# # $$|
|LV + cyclophosphamide + immunization||2,65± 0,68$|
|Immunization DL||11,57± 0,92|
|Immobilization + immunization||7,65± 0,28# #|
|Cyclophosphamide + immunization||6,52± 0,37# #|
|NEP + immunization||10,52± 1,07|
|NEP + immobilization + immunization||9,12± 0,80$|
|NEP + cyclophosphamide + immunization||7,92± 0,49$|
|LV 1 + immunization||10,02± 1,00|
|LV 1 + immobilization + immunization||6,65± 0,88# # $|
|LV 1 + cyclophosphamide + immunization||6,82± 0,65# #|
|LV + immunization||9,02± 0,69#|
|LV + immobilization + immunization||7,12± 0,57# #|
|LV + cyclophosphamide + immunization||7,02± 1,01# #|
|LV + immunization||11,82± 0,26|
|LV + immobilization + immunization||11,12± 1,16$$|
|LV + cyclophosphamide + immunization||9,92±, and 0.40$|
|LV + immunization||of 10.72± 1,27|
|LV + immobilization + immunization||9,92± 0,89$$|
|LV + cyclophosphamide + immunization||7,92± 0,81# $|
|Intact control||91,2± 7,20|
|Immobilization||80,9± 8,20* *|
|Cyclophosphamide||51,2± 6,60* * *|
|NEP + immobilization||114,3± 6,54$$|
|NEP + cyclophosphamide||103,2± 3,69$$$|
|LV||of 120.5± at 8.36* *|
|LV + immobilization||105,2± 9,6$$|
|LV + cyclophosphamide||95,2± 5,77$$|
|LV + immobilization||115,6± 13,65* $|
|LV + cyclophosphamide||90,3± 5,56* $|
|LV||150,8± 7,60* *|
|LV + immobilization||138,1± 15,60|
|LV + cyclophosphamide||128,8± 6,78* $$|
|LV||145,6± 8,65* *|
|LV + immobilization||130,2± to 10.62|
|LV + cyclophosphamide||11b,3± 9,78* $$|
|Note. * - reliability of differences with the background group; # - with the control group EB $ - with an appropriate control group (receiving only medication).|
1. Means, having an immunostimulating action, including the extraction of plant material, characterized in that it contains su is th water or dry alcoholic extract of meadowsweet Filipendula ulmaria (L.) Maxim, obtained when the ratio of raw material:solvent 1:9.
2. The tool, according to claim 1, characterized in that it consists of the dried powdered aerial part of meadowsweet.
3. The tool, according to claim 1, characterized in that it contains 40%alcohol extract.
4. The tool, according to claim 1, characterized in that it contains 70%alcohol extract.
FIELD: medicine, surgery, urology.
SUBSTANCE: one should apply bactisporin probiotic preparation introduced per os at 1-10 x 109 microbial cells twice or thrice for 10-20 d in combination with staphylo-proteic-pyocyanic adsorbed (SPPA) vaccine; moreover, the mentioned combination of preparation should be applied, also, for instillation of wounds, serous cavities, cavities of urinary and biliary ducts at the quantity of 1-5 x 109 microbial cells in isotonic sodium chloride solution. The present innovation provides better humoral and cellular immunity to already developed infectious process, moreover, combined application of SPPA vaccine and bactisporin leads to increased body immune response to antigens of associated vaccine at the background of secondary immunodeficient state induced by infectious process.
EFFECT: higher efficiency of therapy.
1 cl, 5 ex, 3 tbl
FIELD: medicine, immunology, nucleic acids.
SUBSTANCE: invention relates to a method for stimulation of the immune response using nucleic acids-containing immunostimulating compositions, oligonucleotide-containing composition and to a method for treatment or prophylaxis of allergy or asthma. For stimulation of the immune response thymidine-enriched nucleic acid comprising poly-T sequences and/or comprising above 60% of thymidine-containing nucleotide residues is administrated. Invention provides the development of new method for stimulation of the immune response due to administration of the proposed immunostimulating nucleic acid.
EFFECT: valuable medicinal properties of nucleic acid.
27 cl, 12 dwg, 12 ex
FIELD: medicine, immunology.
SUBSTANCE: invention proposes an agent enhancing the immunogenic properties of tetanus anatoxin (adjuvant). Invention proposes the vegetable triterpenic compound miliacin as an agent enhancing immunogenic properties of tetanus anatoxin. Agent enhances the immune response value in its applying as a vaccine preparation of tetanus anatoxin. The agent miliacin elicits its stimulating effect for both the first and repeated administration of vaccine that allows suggesting its possible applying for prophylactic vaccinations with tetanus anatoxin. Taking into account the high tolerance of miliacin in the broad range of its doses it is suggested its practical applying as an agent promoting to the enhanced formation of vaccinal immunity in prophylactic vaccinations with tetanus anatoxin.
EFFECT: valuable medicinal properties of agent.
FIELD: medicine, parapharmaceutical industry.
SUBSTANCE: invention relates to industry manufacturing preparations for curative and prophylactic aims and can be used as a curative and prophylactic, bactericidal, antiviral, anti-inflammatory, analgetic agent promoting to regulation of respiratory organs. The preparation eliciting anti-inflammatory and antibacterial properties comprises dry concentrate of propolis alcoholic tincture, ascorbic acid, fruit essence dry concentrate, citric acid, calcium stearate and sugar taken in the definite ratio of components. The preparation expands assortment of medicinal agents used for treatment of acute and chronic diseases of respiratory organs and represents alternative variant for cases with individual intolerance of some components.
EFFECT: valuable medicinal properties of preparation.
FIELD: medicine, gastroenterology, parapharmaceutical industry, phytotherapy.
SUBSTANCE: invention relates to industry manufacturing preparations for curative and prophylactic aims and can be used for prophylaxis and accessory treatment of digestion organs disease, in particular, diseases of pancreas. Invention proposes the preparation for prophylaxis and maintenance drug therapy in treatment of pancreas diseases in the tableted form based on medicinal plants. Invention proposes the preparation comprising dry concentrates of decoctions prepared from elecampane roots, burdock roots, barberry fruits, thyme seeds, flax seeds, buckwheat milled seeds, ascorbic acid, calcium gluconate, starch, calcium stearate and sugar taken in the definite ratio of components. Invention is directed for expanding assortment of medicinal agents used for therapy and prophylaxis of functional disorders in digestion tract function. The preparation exerts an astringent, antiseptic, moderate spasmolytic and analgetic effect, it normalizes acidity of gastric juice and improves digestive processes.
EFFECT: valuable medicinal properties of preparation.
FIELD: pharmaceutical industry.
SUBSTANCE: invention provides antiinflammatory and wound-healing ointment based on natural components, which invention, along with vegetable oils, may further contain ursine fat, ursine bile, propolis, lanoline, honey, and mummified guano. Variously formulated ointments can be used for treating hemorrhoids, burns, antritis, post-stroke condition, gunshot and stab-punctured wounds, trophic ulcer, postoperative fistula, oophoritis, diabetic microangiopathy of lower extremities, as well as papillomas, birthmarks, seborrhea, and psoriasis.
EFFECT: expanded therapeutical possibilities.
6 cl, 17 ex
FIELD: medicine, pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to compositions used for treatment and/or prophylaxis of chlamydium infections caused by C. pheumoniae. Pharmaceutical composition used for treatment and/or prophylaxis of chlamydium infection caused by C. pneumoniae comprises the taken phenolic compound, or extract, or fraction, or incomplete fraction comprising the taken phenolic compound or corresponding synthetic compound, or mixture of indicated compounds obtained from plants. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction obtained from plants and comprising indicated compound or corresponding synthetic compound on C. pneumoniae represents the definite percent of inhibition for formation of inclusions. The composition useful for health eliciting an anti-chlamydium effect with respect to C. pneumoniae comprises the taken phenolic compound or extract, or fraction, or incomplete fraction containing indicated compound or corresponding synthetic compound, or mixture of indicated compounds obtained from plants. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound obtained from plants on C. pneumoniae represents the definite percent for inhibition in formation of inclusions. Also, invention relates to applying the composition useful for health in preparing foodstuffs or as supplements for nutrition for every day. Also, invention relates to applying phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound or mixture of indicated compounds obtained from plants in manufacturing a medicinal agent used for treatment and/or prophylaxis of chlamydium infections caused by C. pneumoniae. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound obtained from plants on C. pneumoniae represents the definite percent in inhibition in formation of inclusions. Compositions promote to effective prophylaxis and treatment of chlamydium infections caused by C. pneumoniae.
EFFECT: valuable medicinal properties of compounds.
21 cl, 1 dwg, 1 tbl, 6 ex
FIELD: pharmaceutical industry.
SUBSTANCE: invention relates to developing medicaments in the form of ointment based on vegetable components and designed, in particular, to treat psoriasis as well as fungus diseases and can also be used in cosmetology. Psoriasis treatment cream includes water extracts of bur-marigold (Bidens tvipartita), white birch leaves (Betula alba L), greater celandine (Chelidonium majus), calendula (Calendula officanalis L), cudweed (Gnphalium uliginosum L), medical vaseline, lanolin, camphor, linseed oil, and medical solid oil at specified proportions of components.
EFFECT: increased treatment efficiency, avoided use of chemical additives, and prolonged shelf time.
FIELD: flower growing, in particular, beautification of schools and kinder gardens situated in Extreme North.
SUBSTANCE: aloe juice is used as means for stimulating rooting of house plant cuttings.
EFFECT: reduced time for rooting of house plant cuttings, simplified and fast beautification of schools and kinder gardens.
3 tbl, 2 ex
FIELD: food industry.
SUBSTANCE: recovery of biologically active substances from garlic comprises treatment of garlic bulbs with a liquid, disintegration of garlic, and infusion thereof for 6-8 h in vegetable oil at 20-25°C, said vegetable oil being, in particular, being pumpkin oil taken at weight ratio 1:3 to garlic. Liquid utilized is catholyte with pH 7-8 and redox potential between -200 and -500 mV obtained in cathode chamber of diaphragm electrolyzer and treatment of garlic bulbs with catholyte is effected for 1.5 h at garlic-to-catholyte volume ratio 1:2.
EFFECT: increased biological value of oil extract due to maximum recovery of sulfur-containing compounds.
FIELD: veterinary science, parasitology.
SUBSTANCE: invention relates to a method for treatment of agricultural animals with helminthism. Method involves administration of pumpkin oil-cake with residual oil content 12%, not less, by oral route, 2 times per a day for 4-6 days in the dose 3-5 g/kg of animal live mass. Also, sodium sulfate is added to diet in the dose 25 g per a head. Course is repeated in 7-10 days. Method provides the effective treatment of helminthism and significant average-day weight gain of animal mass.
EFFECT: improved method for treatment.
FIELD: medicine, surgery.
SUBSTANCE: early bougienage should be carried out, moreover, additionally, starting since the 4th - 7th d it is necessary to apply ozonized vegetable oil per 1 t.s.p 4 times daily 20-30 min before meals every day, the course should last for about 1-1.5 mo, moreover, as vegetable oil one should apply either olive, sunflower of sea-buckthorn one.
EFFECT: higher efficiency of prophylaxis.
1 cl, 2 ex
FIELD: medicine, pharmaceutical industry.
SUBSTANCE: invention proposes a preparation for regulation of respiratory organs function that is based on medicinal plants. The preparation comprises licorice roots dry extract, ginger milled roots, dry concentrates of creeping thyme herb and colt's foot leaves infusions, milled parmelia, hyssop herb dry concentrate, sage herb infusion dry concentrate, oat, ascorbic acid and accessory substances (starch, calcium stearate, sugar) taken in the definite ratio. The preparation is made as tablet with mass 0.55 g. The preparation promotes to effective regulation of respiratory organs function and elicits the expressed general tonic effect. The proposed preparation is used as an accessory agents promoting to regulation of function of respiratory organs.
EFFECT: valuable medicinal properties of supplement.
FIELD: medicine, cardiology, phytotherapy, pharmacy.
SUBSTANCE: invention relates to the field in development of an agent of vegetable origin used for improvement of the functional state and prophylaxis of organic alterations in cardiovascular system, in particular, atherosclerosis. The biologically active supplement used for prophylaxis of cardiovascular diseases, in particular, atherosclerosis comprises clover dry extract, haw-thorn flowers powder, ascorbic and nicotinic acids, and accessory substances taken in the definite ratio. The biologically active supplement is made in the form of tablet or capsule. No adverse responses observed in intake of the supplement. The blood cholesterol level was reduced to the normal value in 68% of patients and reducing morbidity with acute respiratory-viral infections has been noticed. In patients with ischemic heart disease with cholesterolemia the improvement of the state is noted on the background of conventional therapy: the moderate reducing the arterial pressure value in its elevation, improved in the state of health, enhanced working capacity, reduced retrosternal pains, ear noise, vertigo, headache.
EFFECT: valuable medicinal properties of supplement.